Kornimate/medical-research-clean huggingface dataset:
transcranial magnetic stimulation (tms) for trigeminal neuralgia

Conditions: Facial Pain

Summary: the primary objective is to establish the feasibility of using tms for cofp pain management in the interim period before surgery. this will be investigated by comparing the non-intervention group's self-reported pain to those who recieved tms at several timepoints.

participants will be randomized to either receive transcranial magnetic stimulation (tms), sham-tms (a non-therapeutic tms coil which sounds and feels similar to normal tms), or standard treatment during the weeks of wait time before surgery for chronic orofacial pain (cofp). tms is a noninvasive, painless magnetic device which, when applied to the head for a few minutes, has been shown to reduce pain in people with cofp. the sham tms is a sub-therapeutic level of magnetcic stimulation which makes the same sound as normal tms and causes a similar tingling of the skin. both those who receive this new pain intervention and those who do not will be asked to fill out a short online survey about their pain at several points during the study. the survey takes about 10 minutes to fill out and each of the 5 tms sessions last 10 minutes.

Eligibility criteria:
inclusion criteria: * documented diagnosis of classic trigeminal neuralgia or persisten idiopathic facial pain * considered an appropriate candidate for surgical or stereotactic intervention - microvascular decompression or stereotactic radiosurgery- ( includes factors such as overall health, chronic medication, comorbidities) and patient preference * between ages 18-100 * able to participate in 5 consecutive tms treatments * has at least 3 weeks between pre-op visit and scheduled date of surgery * able to provide consent and complete online questionnaires on their own exclusion criteria: * multiple sclerosis or trauma-related etiology of facial pain (i.e. secondary facial pain) * contraindication to tms, per device guidelines: metallic implant in or near head implanted stimulator on or near head recent suicidal ideation history of epilepsy, stroke, or unexplained seizure - need for urgent/emergent surgical decompression.

Keywords: trigmenial neuralgia chronic orofacial pain
association of circulating chemerin levels and arterial stiffness

Conditions: Obesity; Atherosclerosis

Summary: chemerin is a novel adipokine that might provide a link between chronic inflammation and obesity. pulse wave velocity(pwv) is a useful method for examining arterial stiffness, meaning early-stage atherosclerosis. therefore, in the present study, the investigators examined the relationship between circulating chemerin and arterial stiffness measured using pwv in obese persons.


Eligibility criteria:
inclusion criteria: * self referred persons for visiting routine medical check in our clinic exclusion criteria: * malignancy * severe renal or hepatic disease
promoting the use of cpap therapy among osa patients

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is the most common sleep breathing disorder in the u.s. continuous positive airway pressure (cpap) therapy is the most effective treatment for osa. however, up to 50% of patients who accept using cpap therapy fail to adhere to it. this study will evaluate an information systems (is)-based solution that sends tailored, motivational, educational messages and tailored feedback messages to promote cpap usage among noncompliant osa patients. the primary aim of this study is to determine the efficacy of the proposed is solution and its effect on fostering the use of cpap therapy among osa patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of osa * prescribed treatment of cpap therapy * possession of a mobile phone that has multimedia messaging capabilities * capacity to consent. exclusion criteria: * unable to speak and read english
smart phone for stroke upper limb motor function training

Conditions: Stroke

Summary: stroke rehabilitation for stroke patients can enhance the upper and lower limb function, daily of daily activity improvement, and be beneficial to the family members' quality of life. literature studies have supported the use of tele-rehabilitation to be as effective as stroke home rehabilitation. stroke tele-rehabilitation model can use smartphones and apps to practice the mobile health model. nevertheless, effects of tele-rehabilitation analysis for the proximal recovery of the stroke upper limbs still need to be explored. the main purpose of this research is to develop a smart phone with app system for stroke upper limb motor training, and further analyze its feasibility and treatment effects. the investigators randomly assigned chronic home stroke cases to the experimental group (n=20) and control group (n=20), each group received 8 weeks of treatment.

stroke rehabilitation (including occupational therapy and physical therapy) for stroke patients can enhance the upper and lower limb function, daily of daily activity improvement, and be beneficial to the family members' quality of life. literature studies have supported the use of tele-rehabilitation to be as effective as stroke home rehabilitation. stroke tele-rehabilitation model can use smartphones and apps to practice the mobile health model. this technology with remote rehabilitation have the important characteristics, including ease of use, high-intensity, repetitive exercises, and providing feedback information, to facilitate the recovery of training functions. nevertheless, effects of tele-rehabilitation analysis for the proximal recovery of the stroke upper limbs still need to be explored. the main purpose of this research is to develop a smart phone with app system for stroke upper limb motor training, and further analyze its feasibility and treatment effects. the investigators randomly assigned chronic home stroke cases to the experimental group (n=20) and control group (n=20), each group received 8 weeks of treatment.

Eligibility criteria:
inclusion criteria: * first onset * unilateral hemiplegia * no obvious cognitive impairment (mini-mental state examination (mmse) score \> 23) * the fma upper limb movement score is above 30 points * those who have used a smartphone for more than 3 months before the onset of the disease or at present * those who have no obvious vision loss and can read the text on mobile phones clearly * those who own a smart phone exclusion criteria: * language barriers or aphasia * other orthopedic diseases (such as severe shoulder pain, joint contractures) or nerve damage (such as peripheral nerve damage) that affect the movement of the upper limbs * feel severe absence, fma sensory score \<12 points * other progressive diseases such as cancer, amyotrophic lateral sclerosis, multiple sclerosis, etc
prognostic value of body composition in lung cancer

Conditions: Body Composition and Non-small Cell Lung Cancer

Summary: the effect of body composition on the survival rate is one of the research topics of interest in cancer patients and gaining attention in the last years. body mass index is often used a proxy measure of total adiposity and previous studies examining the relationship between bmi and cancer outcomes have been showed distinct results . obese patients with malignancies such as colorectal, breast, and pancreatic cancers, have been shown to have a worse prognosis than normal-weight patients . nevertheless, obese patients with non small cell lung cancer(nsclc) have been observed to have a better clinical outcome than normal/low-weight cancer patients . in this study, we examined the effects of subcutaneous adipose tissue, visceral adipose tissue and skeletal muscle volumes on survival in metastatic nsclc patients under different treatment regimens. since there is no standard method for adipose tissue measurement, we evaluated the abdominal cavity with multi-slice and single-slice computed tomography measurements.


Eligibility criteria:
inclusion criteria: 1. having a pathological diagnosis of non small cell lung cancer 2. having a stage-iv disease 3. to have received at least one course of treatment 4. presence of positron emission tomography /computed tomography (pet/ct) examination before treatment and having it taken in our hospital 5. the data about the study can be accessed in our center. 6. to be over 18 years old exclusion criteria: 1. unable to access patients data 2. pet/ct cds cannot be accessed or are not suitable for evaluation.
a randomized, double-blind, placebo-controlled clinical study of the oral il-12/23 inhibitor, sta-5326 mesylate, administered to patients with rheumatoid arthritis to determine safety, tolerability, pharmacokinetic and synovial tissue outcomes

Conditions: Active, Moderate to Severe Rheumatoid Arthritis

Summary: it is not fully clear how rheumatoid arthritis originates and develops, but it is understood that multiple genetic and environmental factors interact to trigger its onset. the immune system attacks the joint synovium, which damages the cartilage and bone in the joint by increasing the number of inflammatory cells and forming new blood vessels in the joint space. sta-5326 mesylate inhibits the production of il-12 and il-23 and therefore may inhibit th-1 cytokine production. a reduction in the th-1 response has the potential to minimize or eliminate joint damage caused by the immune response in rheumatoid arthritis. this study is designed to assess whether the proposed mechanism of action is associated with a reduction in inflammation in the synovium of patients who have rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * male or female 18 years of age or older. * has a diagnosis of ra in conformance with the american college of rheumatology (acr) criteria for at least 6 months. * has at least one knee, wrist, or ankle that has active synovitis and is amenable to arthroscopic procedures for the acquisition of synovial tissue via biopsy. * must be taking methotrexate for a minimum of 4 months prior to day 1, with a stable dose regimen for at least 2 months, and * have plans to remain on the stable dose regimen of methotrexate for the duration of this study. * if female of childbearing potential, must be neither pregnant nor breast feeding, and * must have a negative pregnancy test (serum β-hcg) within 1 week of day 1. must be willing to use "double-barrier" contraception methods for the duration of the study. exclusion criteria: * is taking any disease-modifying anti-rheumatic drug (dmard) other than mtx concomitantly or within 1 month prior to day 1. * a positive (≥10 mm) tuberculin (ppd) skin test, unless the patient has had prior bcg immunization or has received prior suppressive treatment such as 1 year of inh. * has received any investigational drug or experimental procedure for the treatment of ra within 3 months of day 1 for a biologic compound or within 1 month of day 1 for a non-biologic compound. * has any clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular, pulmonary, endocrine, psychiatric, hematologic, urologic, or other acute or chronic illness) that, in the opinion of the investigator, would make the patient an unsuitable candidate for this trial.
study of normal intestinal development and disease in premature and term neonates

Conditions: NEC; Necrotizing Enterocolitis; Intestinal Disease; Human Development

Summary: current research on early intestinal development is primarily performed in mouse models. while useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs between the two species. further, prior research has demonstrated that some proteins and pathways that are critical in human development have no clear role in mice. this study aims to improve the overall understanding of critical aspects of intestinal development in humans. in addition, this study will investigate the impact of intestinal diseases that are found in the early stages of life such as necrotizing enterocolitis (nec).


Eligibility criteria:
inclusion criteria: * any neonate or infant through 2 years of age having intestinal surgery or intestinal biopsies from an esophogastroduodenoscopy (egd) or colonoscopy. exclusion criteria: * children \> 2 years of age. * infants 0-2 years old not undergoing gi surgery or intestinal scope with biopsy procedure.

Keywords: nec early intestinal development intestinal intervention necrotizing enterocolitis
evaluation of the value of 18f-fluoromisonidazole (18f-fmiso) positron emission tomography hypoxia imaging in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis (ipf) is a rare, chronic, lethal disease of unknown etiology and with a variable course. there is currently no test in routine care that can assess both the anatomical and functional damage of the disease at an early stage. this is the first human study in ipf to evaluate the value of a non-invasive tracer, 18f-fluoromisonidazole (18f-fmiso), targeting hypoxia in ipf patients. this is a phase i, proof-of-concept, single-center, open-label, parallel group study. it will include 2 groups: * 1 group of 10 ipf patients * 1 group of 10 healthy volunteers matched to ipf patients for age and gender


Eligibility criteria:
inclusion criteria: for all patients (ipf and healthy volunteers) : * person who has given written consent * age ≥ 50 years * absence of disease, comorbidity, or treatment that may interfere with the evaluation of the study objective, as decided by the investigator for patients with ipf only: * diagnosis of ipf according to the criteria of the current international recommendations (ats/ers/jrs/alat of 2011) and validated in a multi-disciplinary meeting in a competence or reference center * patients who have had a high-resolution thoracic ct scan less than 1 month previously as part of the management of their disease * patients who have had a pft less than 1 month previously as part of the management of their disease for healthy volunteers only: * absence of functional respiratory signs - absence of dyspnea on exertion and at rest and absence of chronic cough. * normal clinical examination with no crackles on pulmonary auscultation * no personal history of chronic hypoxemic respiratory disease exclusion criteria: * person who is not covered by national health insurance * cancer or history of cancer in the past 5 years (except basal cell skin cancer) * chronic lung disease other than ipf or a history incompatible with the diagnosis of idiopathic pulmonary fibrosis (thoracic radiotherapy, pneumotoxic chemotherapy, etc.) * exacerbation of ipf during treatment * active smoking * patient requiring long-term oxygen therapy (excluding ambulatory oxygen therapy alone) * contraindication to pet or ct scan or presence of a condition disturbing the interpretation : * known allergy to 18f-fmiso * pregnancy or breastfeeding * claustrophobia * uncontrolled type i/ii diabetes (hba1c \>7%) * surgical intervention in the previous month * radiotherapy session in the previous 3 months * concomitant granulomatous condition (sarcoidosis type) or pulmonary inflammation * moderate or severe renal insufficiency (gfr \< 70 ml/min/1.73 m²) * person under legal protection (curatorship, guardianship) * adult unable to express consent * secondary exclusion criteria only for healthy volunteers * abnormal 6 min walk test at screening * abnormal pft at screening with fvc ≤ 80% of predicted value and dlco ≤ 75% of predicted value
c.a.t.c.h.-i.t.competent adulthood transition with cognitive, humanistic and interpersonal teaching

Conditions: Depression

Summary: the purpose of this study is to adapt depression prevention interventions of proven benefit to the primary care setting in a manner that would be acceptable and potentially available to young adults in the community.

our study goal is to develop a prototype combination primary care-web based depression intervention for young adults ages 18-24years in urban community and university settings. the content development will include: (1) two brief (15 minutes) primary care counseling sessions, (2) one introductory web based module, (3) four web-based cognitive behavior teaching modules, (4) three web-based modules discussing relationship building skills (ipt), and (5) a final web module discussing self-recognition, evidence-based treatment, and stigma. eight young adult volunteers will evaluate the program in three loops of evaluation and revision in a modified focus group approach. this protocol was approved by the johns hopkins joint committee on clinical investigations. primary outcomes: the primary outcome variables relate to the functionality and acceptability of the intervention. these variables include readability, ease of understanding, acceptability, and helpfulness of each component of the intervention, and a global rating of each secondary outcomes: process measures (time on site, exercise completion), outcomes (mood and intermediate outcomes-social adjustment, dysfunctional thinking), and knowledge and opinions of current treatments for depression. these data will be helpful in planning for a future focus groups of 5-10 individuals have been used successfully to provide initial product evaluations or to develop general themes in attitude research. summary statistics will be collected.

Eligibility criteria:
inclusion criteria: * eligibility criteria include being between ages 18-24 and having a family history of depression. preference will be given in selection of participants to those of who have not been treated for depression in the past. exclusion criteria: * moderate or greater risk of having depression (cesd score \> 16) or current treatment for depression. those who have a history of past treatment of depression will not be excluded.

Keywords: depression, educational site for depression
evaluation of the effect of rifampin and rabeprazole on the pharmacokinetics of camlipixant

Conditions: Cough; Healthy

Summary: this is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (blu-5937) 50 mg tablet in healthy participants under fasting conditions.


Eligibility criteria:
inclusion criteria: * healthy males or non-pregnant, non-lactating healthy females exclusion criteria: * history of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disorder, as judged by the investigator.
evaluation of the quality of life of patients requiring intestinal cleansing using oral medications to imaging procedure by patient reported outcome

Conditions: Bowel Preparation

Summary: objective: the primary objective of this study is to assess the quality of life of people treated with oral phosphate compared with polyethylene glycol + electrolytes to imaging procedures, according to the outcome variables reported by patients. type of study: a non-interventional observational analytic prospective cohort study. sample: we will include people who need bowel cleansing for the realization of imaging tests exposures: - oral sodium phosphate normal regimen * oral sodium phosphate with modified diet * polyethylene glycol + electrolytes follow-up time: 8 days after the bowel preparation outcomes: boston scale measure safety differences between groups in blood test (sodium, potassium, calcium)


Eligibility criteria:
inclusion criteria: * patients which have order for an imaging procedure that requires bowel cleansing * older than 18 years and younger than 65 years old * accept to participate in this study
symptoms based awareness confirmation study - comiss validation

Conditions: Cow Milk Allergy

Summary: the cow's milk-related symptom score (comiss) tool has been developed to define a score to recognize cow's milk related symptoms in infants and young children. many infants and toddlers with symptoms that can be related to intake of cow's milk and cow's milk protein allergy (cmpa) are often not diagnosed due to the lack of specific markers. the goal of this trial is to validate the comiss tool in infants suspected of cmpa and investigate if the comiss tool could be an alternative to the open challenge test needed to confirm the diagnosis of cow milk protein allergy.


Eligibility criteria:
inclusion criteria: * male or female infant aged up to 6 months old * has been fed exclusively on cow's milk infant formula for at least one week * has cmpa symptoms that have been present for at least one week, and that developed within the first two months of starting cow's milk infant formula * in the opinion of the investigator, requires a two week elimination diet with amino acid formula (aaf). * had a gestational age at birth of 37 to 42 weeks * had a birthweight of 2500 g to 4500 g * informed consent signed by both parents, liable parent or legal guardian (if applicable). exclusion criteria: * has ever received either an extensively hydrolysed infant formula or an aaf prior to enrolment * has a fever above 38.5°c at enrolment * has ever experienced a medically diagnosed serious anaphylactic reaction * use of antibiotic drugs at enrolment. infants may be enrolled if antibiotics have been stopped at least 7 days prior to enrolment. (antibiotic treatment can be initiated during the study if an infant develops a condition after enrolment that requires antibiotic treatment). * infant with a health condition or family situation that makes the infant unsuitable to participate in the trial according to the opinion of the investigator * infant or infant's carers are unable to comply with trial procedures * currently participating or has participated in another clinical trial within 4 weeks prior to trial start.

Keywords: allergy atopic dermatitis immunoglobulin e (ige) cmpa